Fund Companies Rights Offerings Managed Distributions Leveraged Funds IPOs Asset Classes CEF Advisors

My Fund Comparison
Initilizing list...

Tekla Life Sciences Investors  as of 06/15/2021

NYSE / HQL Asset Class:  Sector Equity Funds 1 YR Lipper Avg:  37.62%

Growth of $10K

Avg Annual Total Return %
  10 YR 5 YR 1 YR YTD
Market Return 17.16% 14.59% 37.27% 12.23%
Lipper Pct. Rank 10 29 78 62
NAV Return 15.65% 13.72% 20.60% 4.20%
Lipper Pct. Rank 13 31 87 87
Premium/Discount History

Premium/Discount
10 YR Avg 5 YR Avg YTD Avg
-4.661% -6.248% -6.290%

NAV $21.24 Market Price $20.85
Net Change -$0.38 Market Change -$0.09
Premium/Discount -1.84%
1 YR NAV Return 20.595%
1 YR NAV Rank 87
12-Mo Yield as of 4/30/2021 Yield Def
Income Only Yield 0.00%
Distribution Yield (Market) 12.44%
Most Recent Income Dividend $0.410
Ex-Div Date 5/27/2021
Most Recent Cap Gain Dividend $0.410
Ex-Div Date 5/27/2021
Dividend Frequency Annually
YTD Dividends --
YTD Capital Gains $0.430
Inception Date 5/8/1992
Fund Advisor Tekla Capital Management LLC
Manager & Tenure Team Managed
Phone 800-451-2597
Website www.teklacap.com
Total Net Assets (mil) as of 5/31/2021 $493.0
% Leveraged Assets as of 9/30/2020 --
Portfolio Turnover 51.00%
Mgmt Fees 0.993%
Expense Ratio 1.220%
Fund Objective
The Fund seeks long-term capital appreciation by investing primarily in equity and related securities of U.S. and foreign companies principally engaged in the development, production or distribution of products or services related to scientific advances in health care, agriculture and environmental management.
Top Holdings (as of 12/31/2020)
Illumina Inc ORD 5.11%
Amgen Inc ORD 5.09%
Gilead Sciences Inc ORD 4.75%
Regeneron Pharmaceuticals Inc ORD 4.67%
Vertex Pharmaceuticals Inc ORD 4.41%
Alexion Pharmaceuticals Inc ORD 4.15%
Seagen Inc ORD 3.51%
Biogen Inc ORD 3.17%
Sarepta Therapeutics Inc ORD 2.12%
Moderna Inc ORD 1.99%
Top Sectors (as of 12/31/2020)
Health Care 89.55%
Non Classified Equity 7.54%

Closed-End Funds Mid-year Review 

Axel Merk and Peter Maletis of Merk Investments discuss their outlook and insights on Gold, Precious Metals and Mining for investors concerned about inflation or seeking diversification.

LISTEN TO THE PODCAST BELOW:



The views and opinions expressed in the replay are for informational and educational purposes only as of the date of production/writing and may change without notice at any time based on factors such as market conditions or legal and regulatory developments. This material may contain “forward-looking” information that is not purely historical in nature. Such information may include, among other things, projections, forecasts, estimates of market returns, and proposed or expected portfolio composition. Past performance is no guarantee of future results. Investing involves risk; principal loss is possible. This material is not intended to be a recommendation or investment advice, does not constitute a solicitation to buy, sell or hold a security or an investment strategy, and is not provided in a fiduciary capacity. Shares of closed-end funds are subject to investment risks, including the possible loss of principal invested. Closed-end funds frequently trade at a discount to their net asset value (NAV).

Featuring:

Moderator:
Dennis Emanuel
Director ETF & CEF Strategy

Dave Lamb
Managing Director in the Global Products Group

Jonathan Isaac 
Director of Product Management

 

Resources

Aberdeen Closed-End TV

Asset TV — CEF Channel

CEF Connect

Cohen & Steers CEFs Knowledge Center

Harvest — CEFA Channel

Legg Mason CEFs

Seeking Alpha — CEFA Channel


SySys Logo

Lipper Logo
Powered by a SySys data & content management system.

© Thomson Reuters 2019. All rights reserved. Any copying, republication or redistribution of Lipper, a Thomson Reuters company, content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper, a Thomson Reuters company. Lipper, a Thomson Reuters company shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.